Rasmussen encephalitis: Incidence and course under randomized therapy with tacrolimus or intravenous immunoglobulins

Purpose:  Rasmussen encephalitis (RE) leads to progressive tissue and function loss of one brain hemisphere and often intractable epilepsy. This is the first randomized prospective treatment trial in RE.

[1]  T. Rasmussen,et al.  Focal seizures due to chronic localized encephalitis , 1958, Neurology.

[2]  M. Brodie,et al.  Definition of drug resistant epilepsy: Consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies , 2011 .

[3]  P. Feys,et al.  The Armeo Spring as training tool to improve upper limb functionality in multiple sclerosis: a pilot study , 2011, Journal of NeuroEngineering and Rehabilitation.

[4]  D. R. Allington,et al.  New approaches in the management of multiple sclerosis , 2010, Drug design, development and therapy.

[5]  J. Schramm,et al.  Treatment of Rasmussen encephalitis half a century after its initial description: Promising prospects and a dilemma , 2009, Epilepsy Research.

[6]  J. Mehrholz,et al.  Improved walking ability and reduced therapeutic stress with an electromechanical gait device. , 2009, Journal of rehabilitation medicine.

[7]  A. Becker,et al.  CD8+ T-cell clones dominate brain infiltrates in Rasmussen encephalitis and persist in the periphery. , 2009, Brain : a journal of neurology.

[8]  C. Bien.  Diagnostik, Therapie und Verlauf der Rasmussen-Enzephalitis , 2008, Zeitschrift für Epileptologie.

[9]  O. Dulac,et al.  Long term response to steroid therapy in Rasmussen encephalitis , 2007, Seizure.

[10]  C. Elger,et al.  Astrocytes are a specific immunological target in Rasmussen's encephalitis , 2007, Annals of neurology.

[11]  Meral Mirza,et al.  Balance performance in three forms of multiple sclerosis , 2006, Neurological research.

[12]  C. Bien,et al.  Neue Erkenntnis zur Rasmussen-Enzephalitis , 2005, Der Nervenarzt.

[13]  C. Elger,et al.  Pathogenesis, diagnosis and treatment of Rasmussen encephalitis: a European consensus statement. , 2005, Brain : a journal of neurology.

[14]  C. Elger,et al.  An open study of tacrolimus therapy in Rasmussen encephalitis , 2004, Neurology.

[15]  G. Broggi,et al.  Experience with immunomodulatory treatments in Rasmussen’s encephalitis , 2003, Neurology.

[16]  S. Keam,et al.  Tacrolimus: a further update of its use in the management of organ transplantation. , 2003, Drugs.

[17]  C. Elger,et al.  The natural history of Rasmussen's encephalitis. , 2002, Brain : a journal of neurology.

[18]  C. Elger,et al.  Destruction of neurons by cytotoxic T cells: A new pathogenic mechanism in rasmussen's encephalitis , 2002, Annals of neurology.

[19]  J. Schramm.  Hemispherectomy techniques. , 2002, Neurosurgery clinics of North America.

[20]  S. Kaveri,et al.  Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin. , 2001, The New England journal of medicine.

[21]  J. Brandt,et al.  Why would you remove half a brain? The outcome of 58 children after hemispherectomy-the Johns Hopkins experience: 1968 to 1996. , 1997, Pediatrics.

[22]  T. Rasmussen,et al.  Chronic encephalitis and epilepsy in adults and adolescents , 1997, Neurology.

[23]  D. Fish,et al.  Medical treatment of Rasmussen's syndrome (chronic encephalitis and epilepsy) , 1994, Neurology.

[24]  A. Wyler.  Chronic encephalitis and epilepsy: Rasmussen's syndrome , 1991 .

[25]  D. Wade,et al.  Assessing motor impairment after stroke: a pilot reliability study. , 1990, Journal of neurology, neurosurgery, and psychiatry.

[26]  R L Hewer,et al.  Motor loss and swallowing difficulty after stroke: frequency, recovery, and prognosis. , 1987, Acta neurologica Scandinavica.

[27]  R L Hewer,et al.  Functional abilities after stroke: measurement, natural history and prognosis , 2012, Journal of Neurology, Neurosurgery & Psychiatry.

[28]  G. Demeurisse,et al.  [Motor evaluation in vascular hemiplegia]. , 1979, Bruxelles medical.